Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer

scientific article published on 21 June 2016

Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1158/1078-0432.CCR-16-1137
P932PMC publication ID5302169
P698PubMed publication ID27330057

P50authorJonathan C WeltiQ58890564
Adam SharpQ62065516
P2093author name stringJohann S de Bono
Julian Blagg
P2860cites workAR-V7 and resistance to enzalutamide and abiraterone in prostate cancerQ27853062
The resurgence of covalent drugsQ34174891
EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancerQ34462138
Androgen Receptor Splice Variants Dimerize to Transactivate Target GenesQ36021859
An androgen receptor N-terminal domain antagonist for treating prostate cancer.Q36966859
Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospectsQ38212470
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.Q38769817
BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate CancerQ38801131
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.Q39819392
Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate CancerQ41009606
Structural characterization of the native NH2-terminal transactivation domain of the human androgen receptor: a collapsed disordered conformation underlies structural plasticity and protein-induced foldingQ46745891
P433issue17
P407language of work or nameEnglishQ1860
P304page(s)4280-4282
P577publication date2016-06-21
P1433published inClinical Cancer ResearchQ332253
P1476titleTargeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer
P478volume22

Reverse relations

cites work (P2860)
Q58610787Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation
Q90015708Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor
Q64122891Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway
Q55004240HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutami
Q55071360Hsp70 and gama-Semino protein as possible prognostic marker of prostate cancer.
Q64940039Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
Q52659701New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.
Q50230942Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.
Q100316309Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors
Q38729033Synergistic Activity with NOTCH Inhibition and Androgen Ablation in ERG-Positive Prostate Cancer Cells
Q57105625Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer

Search more.